Structure Therapeutics Inc. (NASDAQ:GPCR) Shares Sold by TrueMark Investments LLC

TrueMark Investments LLC reduced its position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 7.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 42,127 shares of the company’s stock after selling 3,353 shares during the period. TrueMark Investments LLC owned about 0.07% of Structure Therapeutics worth $1,142,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. ANTIPODES PARTNERS Ltd lifted its holdings in Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after buying an additional 553 shares during the last quarter. GAMMA Investing LLC lifted its stake in Structure Therapeutics by 4,155.6% during the fourth quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after purchasing an additional 1,122 shares during the last quarter. FNY Investment Advisers LLC purchased a new stake in Structure Therapeutics during the fourth quarter worth approximately $40,000. Assetmark Inc. boosted its holdings in Structure Therapeutics by 72.3% in the fourth quarter. Assetmark Inc. now owns 2,271 shares of the company’s stock valued at $62,000 after purchasing an additional 953 shares in the last quarter. Finally, Jones Financial Companies Lllp increased its stake in Structure Therapeutics by 29.8% in the fourth quarter. Jones Financial Companies Lllp now owns 4,228 shares of the company’s stock valued at $115,000 after purchasing an additional 971 shares during the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on GPCR shares. William Blair initiated coverage on shares of Structure Therapeutics in a research report on Friday, February 28th. They set an “outperform” rating for the company. HC Wainwright restated a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. JMP Securities reaffirmed a “market outperform” rating and set a $91.00 price objective on shares of Structure Therapeutics in a report on Wednesday, December 18th. Finally, Stifel Nicolaus assumed coverage on Structure Therapeutics in a report on Wednesday, January 8th. They issued a “buy” rating and a $50.00 target price for the company. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Stock Down 3.4 %

NASDAQ GPCR opened at $20.34 on Wednesday. The firm has a market cap of $1.17 billion, a P/E ratio of -27.49 and a beta of -2.37. Structure Therapeutics Inc. has a 52-week low of $19.39 and a 52-week high of $62.74. The business’s 50-day moving average price is $24.61 and its 200 day moving average price is $31.51.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. As a group, analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current year.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.